Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the efficacy and safety of once-weekly semaglutide 1.0 mg s.c. with exenatide extended release (ER) 2.0 mg s.c. in subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS: In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks. The primary end point was change from baseline in HbA1c at week 56. RESULTS: Mean HbA1c (8.3% [67.7 mmol/mol] at baseline) was reduced by 1.5% (16.8 mmol/mol) with semaglutide and 0.9% (10.0 mmol/mol) with exenatide ER (estimated treatment difference vs. exenatide ER [ETD] –0.62% [95% CI –0.80, –0.44] [–6.78 mmol/mol (95% CI –8.70, –4.86)]; P < 0.0001 for noninferiority and superiority). Mean body weight (95.8 kg at baseline) was reduced by 5.6 kg with semaglutide and 1.9 kg with exenatide ER (ETD –3.78 kg [95% CI –4.58, –2.98]; P < 0.0001). Significantly more subjects treated with semaglutide (67%) achieved HbA1c <7.0% (<53 mmol/mol) versus those taking exenatide ER (40%). Both treatments had similar safety profiles, but gastrointestinal adverse events were more common in semaglutide-treated subjects (41.8%) than in exenatide ER–treated subjects (33.3%); injection-site reactions were more frequent with exenatide ER (22.0%) than with semaglutide (1.2%). CONCLUSIONS: Semaglutide 1.0 mg was superior to exenatide ER 2.0 mg in improving glycemic control and reducing body weight after 56 weeks of treatment; the drugs had comparable safety profiles. These results indicate that semaglutide treatment is highly effective for subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“None of the current DM medications associated with weight loss, including GLP-1 RAs and SGLT2is, have resulted in more than 5.6% weight loss in clinical trials, and this includes dulaglutide,765 exenatide,766 exenatide-ER,767 liraglutide 1.8 mg,768 lixisenatide,769 semaglutide 1.0 mg/week,770,771 semaglutide 1.0 mg/week added to SGLT2i,772 oral semaglutide 14 mg,773 canagliflozin,774 dapagliflozin”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [766]
In the citing paper
“Study designs for these double-blind, randomized controlled trials have been published previously [18–21].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [18]
In the citing paper
“Semaglutide by subcutaneous injection was shown to be superior to exenatide once weekly, dulaglutide, and liraglutide in lowering HbA1c.19”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [19]
In the citing paper
“Serum calcitonin was measured during these trials, and no notable difference in mean levels was seen between the treatment arms.”
From Safety of Semaglutide (2021) · cites this paper as [22]
In the citing paper
“None of these were medullary carcinoma.”
From Safety of Semaglutide (2021) · cites this paper as [22]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“GLP-1 RAs also reduce body weight by inducing feelings of satiety and fullness and reducing feelings of hunger, thereby lowering energy intake (3,4).”
BackgroundSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 2×
“mology to native human GLP-1 and is structurally similar to liraglutide (10), but important structural modifications make it less susceptible to degradation by dipeptidyl peptidase-4 and increase its specific high-affinity binding to albumin (10).”
BackgroundDeclaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
World Medical Association (WMA) (2009) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/9783110208856.233 · Cited by 1,087
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Cited by
Items 101–200 of 657
Lakhani, M., Kwan, A. T. H., Mihalache, A., Popovic, M. M., Nanji, K., Xie, J. S., Feo, A., Rabinovitch, D., Shor, R., Sadda, S., et al. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.05.007 · Cited by 70
Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide
Gallwitz, B., & Giorgino, F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645507 · Cited by 70
Kalra, S., Das, A. K., Sahay, R. K., Baruah, M. P., TIWASKAR, M. H., Das, S., Chatterjee, S., Saboo, B., Bantwal, G., Bhattacharya, S., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0669-4 · Cited by 72
Cimino, G., Vaduganathan, M., Lombardi, C., Pagnesi, M., Vizzardi, E., Tomasoni, D., Adamo, M., Metra, M., & Inciardi, R. M. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14560 · Cited by 68
Rajamand Ekberg, N., Bodholdt, U., Catarig, A.-M., Catrina, S.-B., Grau, K., Holmberg, C. N., Klanger, B., & Knudsen, S. T. (2021) · Primary Care Diabetes · doi:10.1016/j.pcd.2021.06.008 · Cited by 63
DeSouza, C., Cariou, B., Garg, S., Lausvig, N., Navarria, A., & Fonseca, V. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz072 · Cited by 57
Once-Weekly Semaglutide for Weight Management: A Clinical Review
Fornes, A., Huff, J., Pritchard, R. I., & Godfrey, M. (2022) · Journal of Pharmacy Technology · doi:10.1177/87551225221092681 · Cited by 50
Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence
Herman, R. J., & Schmidt, H. D. (2024) · Physiology & Behavior · doi:10.1016/j.physbeh.2024.114565 · Cited by 62
Chao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s365416 · Cited by 58
Piccirillo, F., Mastroberardino, S., Nusca, A., Frau, L., Guarino, L., Napoli, N., Ussia, G. P., & Grigioni, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210164 · Cited by 58
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01106-4 · Cited by 55
Self-citationAnti-inflammatory effect of semaglutide: updated systematic review and meta-analysis
Masson, W., Lobo, M., Nogueira, J. P., Rodriguez-Granillo, A. M., Barbagelata, L. E., & Siniawski, D. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1379189 · Cited by 57
Xie, X., Yang, S., Deng, S., Liu, Y., Xu, Z., & He, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1613610 · Cited by 57
The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes
Rasmussen, M. F. (2020) · Diabetology International · doi:10.1007/s13340-019-00423-8 · Cited by 57
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
Ibrahim, S. S., Ibrahim, R. S., Arabi, B., Brockmueller, A., Shakibaei, M., & Büsselberg, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10192-9 · Cited by 56
Vadher, K., Patel, H., Mody, R., Levine, J. A., Hoog, M., Cheng, A. Y., Pantalone, K. M., & Sapin, H. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14775 · Cited by 56
Cesaro, A., Pastori, D., Acerbo, V., Biccirè, F. G., Golino, M., Panico, D., Prati, F., Abbate, A., Lip, G. Y. H., & Calabrò, P. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf257 · Cited by 56
Jain, A. B., Ali, A., Gorgojo Martínez, J. J., Hramiak, I., Kavia, K., Madsbad, S., Potier, L., Prohaska, B. D., Strong, J. L., & Vilsbøll, T. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.13731 · Cited by 44
Aviles Bueno, B., Soler, M. J., Perez-Belmonte, L., Jimenez Millan, A., Rivas Ruiz, F., & Garcia de Lucas, M. D. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac096 · Cited by 43
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Salvador, R., Moutinho, C. M. S. G., Sousa, C., Vinha, A. F., Carvalho, M. C., & Matos, C. M. (2025) · Pharmaceuticals · doi:10.3390/ph18030399 · Cited by 55
Granata, A., Maccarrone, R., Anzaldi, M., Leonardi, G., Pesce, F., Amico, F., Gesualdo, L., & Corrao, S. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac069 · Cited by 54
Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes
Petri, K. C. C., Ingwersen, S. H., Flint, A., Zacho, J., & Overgaard, R. V. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13358 · Cited by 53
Zhang, Y., Chen, G., Wang, W., Yang, D., Zhu, D., & Jing, Y. (2024) · Bone · doi:10.1016/j.bone.2024.117338 · Cited by 52
Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management
Chun, J. H., & Butts, A. (2020) · JAAPA · doi:10.1097/01.jaa.0000669456.13763.bd · Cited by 45
Shi, F.-H., Li, H., Cui, M., Zhang, Z.-L., Gu, Z.-C., & Liu, X.-Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00576 · Cited by 50
Yale, J.-F., Bodholdt, U., Catarig, A.-M., Catrina, S., Clark, A., Ekberg, N. R., Erhan, U., Holmes, P., Knudsen, S. T., Liutkus, J., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002619 · Cited by 50
Kommu, S., & Berg, R. L. (2024) · Obesity Reviews · doi:10.1111/obr.13792 · Cited by 50
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
Carlsson Petri, K. C., Ingwersen, S. H., Flint, A., Zacho, J., & Overgaard, R. V. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0458-5 · Cited by 47
PEREZ-MONTES DE OCA, A., PELLITERO, S., & PUIG-DOMINGO, M. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.20.03369-6 · Cited by 36
Saengboonmee, C., Seubwai, W., Lert-itthiporn, W., Sanlung, T., & Wongkham, S. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.09.008 · Cited by 48
Palanisamy, S., Yien, E. L. H., Shi, L., Yi, L., Qi, S. H., Soon, L., Lun, T. W., & Chen, Y. N. (2018) · Pharmacy · doi:10.3390/pharmacy6030057 · Cited by 48
Hu, M., Cai, X., Yang, W., Zhang, S., Nie, L., & Ji, L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015323 · Cited by 49
Okamoto, A., Yokokawa, H., Nagamine, T., Fukuda, H., Hisaoka, T., & Naito, T. (2021) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-021-00899-9 · Cited by 48
Xie, Z., Hu, J., Gu, H., Li, M., & Chen, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1244432 · Cited by 47
Witkowski, M., Wilkinson, L., Webb, N., Weids, A., Glah, D., & Vrazic, H. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0424-2 · Cited by 45
Matza, L. S., Boye, K. S., Stewart, K. D., Coyne, K. S., Wullenweber, P. K., Cutts, K. N., Jordan, J. B., Wang, Q., Yu, M., Currie, B. M., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13902 · Cited by 46
Wright, E. E., & Aroda, V. R. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798127 · Cited by 47
Self-citationZhou, Y., Chen, M., Liu, L., & Chen, Z. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s348025 · Cited by 46
Rudofsky, G., Catarig, A.-M., Favre, L., Grau, K., Häfliger, S., Thomann, R., & Schultes, B. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108931 · Cited by 46
Obesidad y diabetes mellitus tipo 2: también unidas en opciones terapéuticas
Rubio-Almanza, M., Cámara-Gómez, R., & Merino-Torres, J. F. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.08.003 · Cited by 46
Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond
Dutta, P., Kumar, Y., Babu, A. T., Ravindran, S. G., Salam, A., Rai, B., Baskar, A., Dhawan, A., & Jomy, M. (2023) · Cureus · doi:10.7759/cureus.38379 · Cited by 46
Viljoen, A., Hoxer, C. S., Johansen, P., Malkin, S., Hunt, B., & Bain, S. C. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13564 · Cited by 45
Porous silicon and silica carriers for delivery of peptide therapeutics
Yan, J., Siwakoti, P., Shaw, S., Bose, S. K., Kokil, G. R., & Kumeria, T. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01609-7 · Cited by 45
Kim, H. S., & Jung, C. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189936 · Cited by 45
Zaazouee, M. S., Hamdallah, A., Helmy, S. K., Hasabo, E. A., Sayed, A. K., Gbreel, M. I., Elmegeed, A. A., Aladwan, H., Elshanbary, A. A., Abdel‐Aziz, W., et al. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102511 · Cited by 45
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
“Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) trials showed the positive effects of subcutaneous semaglutide on glycemic control [128].”
BackgroundAnson, M., Henney, A. E., Broadwell, N., Zhao, S. S., Ibarburu, G. H., Lip, G. Y. H., Wilding, J. P. H., Cuthbertson, D. J., & Alam, U. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102777 · Cited by 44
Chan, Y.-C., Chuang, S., Kuo, Y., Lian, Y.-Z., & Chen, Y. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.06.083 · Cited by 44
Nuhoho, S., Gupta, J., Hansen, B. B., Fletcher-Louis, M., Dang-Tan, T., & Paine, A. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00706-y · Cited by 41
Yin, D.-G., Ding, L.-L., Zhou, H.-R., Qiu, M., & Duan, X.-Y. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej21-0129 · Cited by 39
Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications
Guglielmi, V., Bettini, S., Sbraccia, P., Busetto, L., Pellegrini, M., Yumuk, V., Colao, A. M. L., Ghoch, M. E., & Muscogiuri, G. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00502-7 · Cited by 44
Semaglutide and the risk of diabetic retinopathy—current perspective
Sharma, A., Parachuri, N., Kumar, N., Saboo, B., Tripathi, H. N., Kuppermann, B. D., & Bandello, F. (2022) · Eye · doi:10.1038/s41433-021-01741-5 · Cited by 43
Lingvay, I., Kirk, A. R., Lophaven, S., Wolden, M. L., & Shubrook, J. H. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01010-4 · Cited by 41
Self-citationA Review on the Efficacy and Safety of Oral Semaglutide
Niman, S., Hardy, J., Goldfaden, R. F., Reid, J., Sheikh‐Ali, M., SUTTON, D. R., & Choksi, R. R. (2021) · Drugs in R&D · doi:10.1007/s40268-021-00341-8 · Cited by 43
Holmes, P., Bell, H. E., Bozkurt, K., Catarig, A.-M., Clark, A., Machell, A., & Sathyapalan, T. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01141-8 · Cited by 42
Brown, R. E., Bech, P. G., & Aronson, R. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14117 · Cited by 42
Hinds, C. E., Peace, E., Chen, S., Davies, I., Eid, L. E., Tomás, A., Tan, T., MINNION, J. S., Jones, B. J., & Bloom, S. R. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15288 · Cited by 42
Jódar, E., Michelsen, M. M., Polonsky, W. H., Rea, R. R., Sandberg, A., Vilsbøll, T., Warren, M., Østoft, S. H., Ziegler, U. E., & Bain, S. C. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14039 · Cited by 42
The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
Jung, H. N., & Jung, C. H. (2022) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22012 · Cited by 42
Alhindi, Y., & Avery, A. (2022) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2022.100944 · Cited by 37
Camilleri, M., & Lupianez-Merly, C. (2024) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002519 · Cited by 41
Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis
Natividade, G. R., Spiazzi, B. F., Baumgarten, M. W., Bassotto, C., Pereira, A. A., Fraga, B. L., Scalco, B. G., Mattes, N. R., Lavinsky, D., Kramer, C. K., et al. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.2489 · Cited by 41
Clemens, K. K., Ernst, J., Khan, T., Reichert, S., Khan, M. Q., LaPier, H., Chiu, M., Stranges, S., Sahi, G., Castrillon-Ramirez, F., et al. (2023) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.03.023 · Cited by 40
Overgaard, R. V., Lindberg, S. Ø., & Thielke, D. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13479 · Cited by 34
Yale, J., Catarig, A., Grau, K., Harris, S., Klimek‐Abercrombie, A., Rabasa‐Lhoret, R., Reardon, L., Woo, V., & Liutkus, J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14468 · Cited by 37
Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets
Santos‐Laso, Á., Gutiérrez‐Larrañaga, M., Alonso‐Peña, M., Medina, J. M., Iruzubieta, P., Arias, M., López‐Hoyos, M., & Crespo, J. (2021) · Biomedicines · doi:10.3390/biomedicines10010046 · Cited by 40
Patoulias, D., Popovic, D. S., Stoian, A. P., Janež, A., Sahebkar, A., & Rizzo, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108529 · Cited by 40
Kokkorakis, M., Katsarou, A., Katsiki, N., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155689 · Cited by 34
Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
Madsbad, S., & Holst, J. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac112 · Cited by 39
GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling
Kooij, K. L., Koster, D. I., Eeltink, E., Luijendijk, M. C. M., Drost, L., Ducrocq, F., & Adan, R. A. H. (2023) · Neuroscience Applied · doi:10.1016/j.nsa.2023.103925 · Cited by 39
Lingvay, I., Benamar, M., Chen, L., Fu, A., Jódar, E., Nishida, T., Riveline, J., Yabe, D., Züger, T., & Rea, R. R. (2025) · Diabetologia · doi:10.1007/s00125-024-06348-5 · Cited by 39
Self-citationKobayati, A., Haidar, A., & Tsoukas, M. A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14637 · Cited by 39
Research Progress on bioactive peptides from animal sources: A comprehensive review
Sun, J., Chen, Y., Yang, Y., Chen, H., Zhang, J., Wang, H., Bai, D., Sun, Z., Song, J., & Dai, L. (2025) · Food Chemistry · doi:10.1016/j.foodchem.2025.145006 · Cited by 38
Buckeridge, C., Cobain, S., Bays, H. E., Matsuoka, O., Fukushima, Y., Halstead, P., Tsamandouras, N., Sherry, N., Gorman, D. N., & Saxena, A. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16534 · Cited by 38
Ren, X., Hua, H., Wu, Y., Zhang, W., Long, X., Bai, Y., & Cheng, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-09807-0 · Cited by 38
Incretin combination therapy for the treatment of non-alcoholic steatohepatitis
Kannt, A., Madsen, A. N., Kammermeier, C., Elvert, R., Klöckener, T., Bossart, M., Haack, T., Evers, A., Lorenz, K., Hennerici, W., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14035 · Cited by 37
Semaglutide for the prevention of atrial fibrillation: A systematic review and meta-analysis
Zhang, H., Ding, L., Liu, K., Mi, L., Zhang, A.-K., Yu, F., Yan, X.-X., Peng, F.-H., Shen, Y.-J., & Tang, M. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103067 · Cited by 37
Clinical potential of treatment with semaglutide in type 2 diabetes patients
Røder, M. E. (2019) · Drugs in Context · doi:10.7573/dic.212585 · Cited by 37
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Tseng, P., Zeng, B., Hsu, C.-W., Hung, C., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04018-w · Cited by 36
Aroda, V. R., Capehorn, M. S., Chaykin, L., Frias, J. P., Lausvig, N. L., Macura, S., Lüdemann, J., Madsbad, S., Rosenstock, J., Tabak, O., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13896 · Cited by 31
Self-citationQian, P., Tian, H., Wang, Y., Lu, W., Li, Y., Ma, T., Gao, X., & Yao, W. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114209 · Cited by 36
Patti, A. M., Giglio, R. V., Allotta, A., Bruno, A., Bella, T. D., Stoian, A. P., Ciaccio, M., & Rizzo, M. (2023) · Biomedicines · doi:10.3390/biomedicines11051362 · Cited by 36
Muzurović, E., & Mikhailidis, D. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1795132 · Cited by 35
Anam, M., Maharjan, S., Amjad, Z., Abaza, A., Vasavada, A. M., Sadhu, A., Valencia, C., Fatima, H., & Nwankwo, I. (2022) · Cureus · doi:10.7759/cureus.32610 · Cited by 35
“In addition, a weight loss response of ≥5% was seen in 52% receiving semaglutide compared to 17% of subjects receiving exenatide ER [22].”
BackgroundInfluentialGlucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
Zhou, Z., Yi, L., Popławska-Domaszewicz, K., Chaudhuri, К. R., Jankovic, J. J., & Tan, E. K. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107770 · Cited by 35
Semaglutide for the Treatment of Type 2 Diabetes Mellitus
Miles, K. E., & Kerr, J. L. (2018) · Journal of Pharmacy Technology · doi:10.1177/8755122518790925 · Cited by 35
Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
Mouhammad, Z. A., Vohra, R., Horwitz, A., Thein, A., Andreasen, J. R., Cvenkel, B., Williams, P. A., Azuara‐Blanco, A., & Kolko, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824054 · Cited by 36
Cracking the combination: Gut hormones for the treatment of obesity and diabetes
Alexiadou, K., Anyiam, O., & Tan, T. (2019) · Journal of Neuroendocrinology · doi:10.1111/jne.12664 · Cited by 34
Marzullo, P., Daffara, T., Mele, C., Zavattaro, M., Ferrero, A., Caputo, M., Prodam, F., & Aimaretti, G. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01799-2 · Cited by 34
Alkhouri, N., Charlton, M., Gray, M. E., & Noureddin, M. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2473062 · Cited by 34
Rodríguez, R., Hergarden, A. C., Krishnan, S., Morales, M., Lam, D., Tracy, T., Tang, T., Patton, A., Lee, C. R., Pant, A., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102156 · Cited by 34
Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis
Alsugair, H. A., Alshugair, I. F., Alharbi, T., Rsheed, A. M. B., Tourkmani, A. M., & Almadani, W. H. (2021) · Healthcare · doi:10.3390/healthcare9091125 · Cited by 34
Cherney, D. Z. I., Hadjadj, S., Lawson, J., Mosenzon, O., Tuttle, K. R., Vrhnjak, B., Rasmussen, S., & Bain, S. C. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.07.167 · Cited by 35
King, A., & Miller, E. M. (2022) · Clinical Diabetes · doi:10.2337/cd22-0027 · Cited by 34
Napoli, R., Berra, C., Catarig, A., Di Loreto, C., Donatiello, E., Berentzen, T. L., Pitocco, D., & Giorgino, F. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15020 · Cited by 32
Obesity and type 2 diabetes: Also linked in therapeutic options
Rubio-Almanza, M., Cámara-Gómez, R., & Merino-Torres, J. F. (2018) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.11.006 · Cited by 36
Mathieu, C., Giorgino, F., Kim, S. G., Larsen, J. S., Philis‐Tsimikas, A., Ramachandran, A., da Rocha, T. J. C. M., Shankarappa, V. B., Terauchi, Y., & Ji, L. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00096-8 · Cited by 33
Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice
Inia, J. A., Stokman, G., Morrison, M. C., Worms, N., Verschuren, L., Caspers, M. P. M., Menke, A. L., Petitjean, L., Chen, L., Petitjean, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108494 · Cited by 33
Recent achievements and future directions of anti-obesity medications
Grandl, G., Novikoff, A., Liu, X., & Müller, T. D. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101100 · Cited by 32
Metadata
- Authors
- Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R.
- Affiliations
- Oregon Health & Science University (US)
- Rotherham Institute for Obesity, Clifton Medical Centre, Rotherham, U.K.
- Centre Hospitalier Sud Francilien (FR)
- University of Siena (IT)
- GWT-TUD GmbH (Germany) (DE)
- The University of Texas Southwestern Medical Center (US)
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk Inc., Plainsboro, NJ
- MedStar Health Research Institute (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-12-15
- Volume
- 41
- Issue
- 2
- Pages
- 258-266
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2774157762
- Cited by
- 596
- References
- 32
- Citations by year
- 2026: 57 · 2025: 91 · 2024: 88 · 2023: 68 · 2022: 68 · 2021: 48 · 2020: 64 · 2019: 55 · 2018: 51 · 2017: 3
- FWCI
- 37.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, exenatide extended-release, type 2 diabetes, GLP-1 receptor agonists, glycemic control, HbA1c, weight loss, gastrointestinal adverse effects, injection site reactions, non-inferiority, oral antidiabetic drugs, drug safety and efficacy comparison, weekly dosing
- MeSH terms
- Exenatide, Semaglutide, Adult, Aged, Aged, 80 and over, Blood Glucose, Body Weight, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Drug Administration Schedule, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Venoms, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.